Clinical Trial Detail

NCT ID NCT03064490
Title Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Duke University

gastroesophageal junction adenocarcinoma

esophagus adenocarcinoma

gastric adenocarcinoma


Carboplatin + Paclitaxel + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.